Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;74(4):557-569.
doi: 10.1007/s43440-022-00390-z. Epub 2022 Jul 26.

GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders

Divya Soni  1 , Puneet Kumar  2
Affiliations
Review

GSK-3β-mediated regulation of Nrf2/HO-1 signaling as a new therapeutic approach in the treatment of movement disorders

Divya Soni et al. Pharmacol Rep. 2022 Aug.

Abstract

Movement disorders are neurological conditions characterized by involuntary motor movements, such as dystonia, ataxia, chorea myoclonus, tremors, Huntington's disease (HD), and Parkinson's disease (PD). It is classified into two categories: hypokinetic and hyperkinetic movements. Globally, movement disorders are a major cause of death. The pathophysiological process is initiated by excessive ROS generation, mitochondrial dysfunction, neuroinflammation, and neurotransmitters imbalance that lead to motor dysfunction in PD and HD patients. Several endogenous targets including Nrf2 maintain oxidative balance in the body. Activation of Nrf2 signaling is regulated by the enzyme glycogen synthase kinase (GSK-3β). In the cytoplasm, inhibition of GSK-3β regulates cellular proliferation, homeostasis, and apoptotic process by stimulating the nuclear factor erythroid 2 (Nrf2) pathway which is involved in the elevation of the cellular antioxidant enzymes which controls the ROS generation. The activation of Nrf2 increases the expression of antioxidant response elements (ARE), such as (Hemeoxygenase-1) HO-1, which decreases excessive cellular stress, mitochondrial dysfunction, apoptosis, and neuronal degeneration, which is the major cause of motor dysfunction. The present review explores the GSK-3β-mediated neuroprotection in various movement disorders through the Nrf2/HO-1 antioxidant pathway. This review provides a link between GSK-3β and the Nrf2/HO-1 signaling pathway in the treatment of PD and HD. In addition to that it highlights various GSK-3β inhibitors and the Nrf2/HO-1 activators, which exert robust neuroprotection against motor disorders. Therefore, the present review will help in the discovery of new therapy for PD and HD patients.

Keywords: GSK-3β; Huntington’s disease; Movement disorders; Neuroprotection; Nrf2/HO-1; Parkinson’s disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Murthy M, Cheng YY, Holton JL, Bettencourt C. Neurodegenerative movement disorders: an epigenetics perspective and promise for the future. Neuropathol Appl Neurobiol. 2021;47(7):897–909. - PubMed - PMC - DOI
    1. Huang X, Li N, Pu Y, Zhang T, Wang B. Neuroprotective effects of ginseng phytochemicals: recent perspectives. Molecules. 2019;24(16):2939. - PMC - DOI
    1. Moscovich M, LaFaver K, Maetzler W. Functional movement disorder in older adults, in functional movement disorder. Berlin: Springer; 2022. p. 197–203. - DOI
    1. Navarro-Lopez EM, Çelikok U, Şengör NS. A dynamical model for the basal ganglia-thalamo-cortical oscillatory activity and its implications in Parkinson’s disease. Cogn Neurodyn. 2021;15(4):693–720. - PubMed - DOI
    1. Callahan JW, Wokosin DL, Bevan MD. Dysregulation of the basal Ganglia indirect pathway in early symptomatic q175 Huntington’s disease mice. J Neurosci. 2022;42(10):2080–102. - PubMed - DOI

LinkOut - more resources

-